Form 4: Kiora Pharmaceuticals Director Acquires Stock Options

Erin Parsons, a director at Kiora Pharmaceuticals, acquired options to purchase 20,000 shares of common stock on April 1, 2025.

Summary

• On April 1, 2025, Erin Parsons, a director of Kiora Pharmaceuticals, acquired stock options.
• The options grant the right to purchase 20,000 shares of Kiora Pharmaceuticals' common stock at an exercise price of $2.93.
• These options were granted under the company's 2024 Equity Incentive Plan.
• The options will become fully exercisable on April 1, 2026, and expire on April 1, 2035.
• Following the transaction, Parsons directly owns 20,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns director interests with shareholders.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Industry Context

This is a standard practice for incentivizing company directors and aligning their interests with those of the shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice across the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen often use equity-based compensation to incentivize their executives and directors.
• The specific terms of the option grants, such as the exercise price and vesting schedule, are generally aligned with industry benchmarks for similar-sized companies.

Stakeholder Impact

• The granting of stock options can positively impact shareholders by aligning the interests of the director with the company's long-term success.

Key Dates

Keywords

stock options, director, Kiora Pharmaceuticals, equity incentive plan, beneficial ownership, Form 4